Gregory D. Lewis

Gregory D. Lewis

Cardiology | Advanced Heart Failure and Transplant Cardiology

55 Fruit St
Boston, MA 02114

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 264 publications

Effect of Aficamten on Cardiac Structure and Function in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.

Effect of Aficamten on Cardiac Structure and Function in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.

Journal: Circulation

Published: August 29, 2026

Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.

Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.

Journal: The New England journal of medicine

Published: August 28, 2026

Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCM.

Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCM.

Journal: Circulation

Published: August 28, 2026

Body Composition, Obesity, and Cardiorespiratory Fitness in the Community.

Body Composition, Obesity, and Cardiorespiratory Fitness in the Community.

Journal: Medicine and science in sports and exercise

Published: August 18, 2026

Large Language Model Recommendations for Heart Failure Therapy.

Large Language Model Recommendations for Heart Failure Therapy.

Journal: Journal of cardiac failure

Published: August 12, 2026

Heterogeneous Treatment Effects in HFpEF: Distinguishing Drug-Specific Response from Prognostic Phenotypes Across Randomized Trials.

Heterogeneous Treatment Effects in HFpEF: Distinguishing Drug-Specific Response from Prognostic Phenotypes Across Randomized Trials.

Journal: medRxiv : the preprint server for health sciences

Published: July 17, 2026

Heterogeneous Treatment Effects in HFpEF: Distinguishing Drug-Specific Response from Prognostic Phenotypes Across Randomized Trials.

Heterogeneous Treatment Effects in HFpEF: Distinguishing Drug-Specific Response from Prognostic Phenotypes Across Randomized Trials.

Journal: medRxiv : the preprint server for health sciences

Published: July 17, 2026

Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial.

Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial.

Journal: JAMA cardiology

Published: June 17, 2026

The Threshold for a Clinically Meaningful Improvement in Cardiopulmonary Exercise Testing Measures for Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy.

The Threshold for a Clinically Meaningful Improvement in Cardiopulmonary Exercise Testing Measures for Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy.

Journal: Journal of cardiac failure

Published: June 10, 2026

Efficacy of Aficamten vs Metoprolol According to Pretrial Beta-Blocker Treatment in Obstructive Hypertrophic Cardiomyopathy: Insights From MAPLE-HCM.

Efficacy of Aficamten vs Metoprolol According to Pretrial Beta-Blocker Treatment in Obstructive Hypertrophic Cardiomyopathy: Insights From MAPLE-HCM.

Journal: JACC. Heart failure

Published: June 08, 2026

Ex Vivo Perfusion Unmasks a Proteomic Signature of Primary Graft Dysfunction in Donor Hearts.

Ex Vivo Perfusion Unmasks a Proteomic Signature of Primary Graft Dysfunction in Donor Hearts.

Journal: JACC. Heart failure

Published: April 27, 2026

Multi-Organ Physiologic Deficits During Exercise Identify Clinical and Molecular Predisposition to Heart Failure with Preserved Ejection Fraction.

Multi-Organ Physiologic Deficits During Exercise Identify Clinical and Molecular Predisposition to Heart Failure with Preserved Ejection Fraction.

Journal: Circulation

Published: April 07, 2026

Showing 1-12 of 264

Last Updated: 09/26/2026